The MIMVaC-Africa consortium is a large interdisciplinary consortium formed by leading vaccine developpers, clinical trial experts and malaria researchers with knowledge in management of large clinical data sets and in regulatory procedures.
The consortium is comprised of ten complementary organisations from Africa, Europe and Asia and is coordinated by the Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso. Partner organisations are in Gabon (CERMEL), Germany (EKUT and EVI), Japan (OSU), Luxembourg (LIH), Mozambique (CISM), the Netherlands (LUMC), Tanzania (IHI), and the United Kingdom (UOXF/KEMRI-WT).
This consortium is receiving financial support from the European Union’s European & Developing Countries Clinical Trials Partnership (EDCTP2), through the grant agreement No. RIA2018SV-2310
To ensure a successful management of the programme, the coordinating site is assisted by the Project Steering Committee (PSC) which benefits from the scientific and ethical advices of the External Independent Scientific Advisory Group (EISAG).